Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN

J. Bousquet, P. Van Cauwenberge, N. Ad'T Khaled, C. Bachert, C. E. Baena-Cagnani, J. Bouchard, C. Bunnag, G. W. Canonica, K. H. Carlsen, Y. -. Z. Chen, A. A. Cruz, A. Custovic, P. Demoly, R. Dubakiene, S. Durham, W. Fokkens, P. Howarth, J. Kemp, M. L. Kowalski, V. KvedarieneB. Lipworth, R. Lockey, V. Lund, S. Mavale-Manuel, E. O. Meltzer, J. Mullol, R. Naclerio, K. Nekam, K. Ohta, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. Popov, P. Potter, David Brendan Price, G. Scadding, F. E. R. Simons, V. Spicak, E. Valovirta, D. -. Y. Wang, B. Yawn, O. Yusuf

Research output: Contribution to journalEditorialpeer-review

132 Citations (Scopus)

Abstract

The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document.

Original languageEnglish
Pages (from-to)1086-1096
Number of pages10
JournalAllergy
Volume61
DOIs
Publication statusPublished - Sept 2006

Keywords

  • ARIA
  • asthma
  • GA(2)LEN
  • IgE
  • pharmacotherapy
  • rhinitis
  • AQUEOUS NASAL SPRAY
  • PLACEBO-CONTROLLED TRIAL
  • QUALITY-OF-LIFE
  • LORATADINE 10 MG
  • INTRANASAL FLUTICASONE PROPIONATE
  • ENVIRONMENTAL EXPOSURE UNIT
  • RANDOMIZED CONTROLLED-TRIAL
  • EBASTINE 20 MG
  • LEUKOTRIENE RECEPTOR ANTAGONISTS
  • ADRENAL AXIS FUNCTION

Fingerprint

Dive into the research topics of 'Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaroration with GA2LEN'. Together they form a unique fingerprint.

Cite this